- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging Prostate and Brain MRI AI Platform Gets FDA Nod
In addition to a previously FDA-cleared brain magnetic resonance imaging (MRI) module, the Advantis Platform features an artificial intelligence-powered prostate MRI module that offers simultaneous viewing of conventional and advanced sequences, and reportedly generates automated PI-RADS assessments.
The Food and Drug Administration (FDA) has reportedly granted 510(k) clearance to the Advantis Platform (Advantis Medical Imaging), which offers artificial intelligence-enabled modules for multiparametric prostate MRI as well as brain MRI analysis.
The Advantis Prostate module streamlines radiology workflows with automated diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI maps, and simultaneous viewing of advanced and conventional sequences in one viewer, according to Advantis Medical Imaging. The company adds that the Advantis Prostate module provides automated PI-RADS reporting with one click.
Images courtesy of Advantis Medical Imaging.
Advantis Medical Imaging said the Advantis Brain module (which previously garnered FDA 510(k) clearance under the name Brainance MD) offers a variety of features including automated processing of dynamic susceptibility contrast (DSC) MRI perfusion scans with expedient exporting of maps and key findings to the existing PACS system. Another benefit of Advantis Brain is fully automated tractography with single-click fiber tracking on diffusion tensor imaging (DTI), according to the company.
“This latest FDA clearance is a testament to our commitment to delivering innovative solutions that streamline workflows and provide clinicians with reliable, accessible and efficient software tools,” noted Zoi Giavri, the chief product office for Advantis Medical Imaging. “Our recent integration of the multiparametric prostate MRI module in our software suite, Advantis Platform, complements the existing brain MRI module while both of them enable healthcare professions to more easily extract meaningful information from MRIs.”
(Editor’s note: For related content, see “Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?” and “FDA Clears New AI Software for MRI Detection of Prostate Cancer.”
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
